Design Therapeutics, Inc.
DSGN
$4.72
-$0.24-4.84%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -14.89% | -23.59% | -22.33% | -35.79% | -14.39% |
| Gross Profit | 14.89% | 23.59% | 22.33% | 35.79% | 14.39% |
| SG&A Expenses | -14.64% | -20.54% | -12.47% | -2.39% | 11.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.22% | -26.26% | -23.48% | -6.50% | 15.68% |
| Operating Income | 20.22% | 26.26% | 23.48% | 6.50% | -15.68% |
| Income Before Tax | 25.84% | 33.97% | 31.97% | 15.38% | -5.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 25.84% | 33.97% | 31.97% | 15.38% | -5.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.84% | 33.97% | 31.97% | 15.38% | -5.61% |
| EBIT | 20.22% | 26.26% | 23.48% | 6.50% | -15.68% |
| EBITDA | 20.43% | 26.50% | 23.71% | 6.67% | -15.58% |
| EPS Basic | 26.65% | 34.57% | 32.43% | 15.80% | -5.13% |
| Normalized Basic EPS | 26.66% | 35.81% | 33.66% | 17.45% | -2.88% |
| EPS Diluted | 26.65% | 34.57% | 32.43% | 15.80% | -5.04% |
| Normalized Diluted EPS | 26.66% | 35.81% | 33.66% | 17.45% | -2.88% |
| Average Basic Shares Outstanding | 1.08% | 0.91% | 0.72% | 0.58% | 0.50% |
| Average Diluted Shares Outstanding | 1.08% | 0.91% | 0.72% | 0.58% | 0.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
